BACE1 antibodies
The invention provides antibodies to specific neural proteins and methods of using the same.
1. An isolated antibody, or fragment thereof, that binds to β-site amyloid precursor protein cleaving enzyme 1 (BACE1) comprising
(a) an HVR-H1 comprising the amino acid sequence GFTFX 13 GYX 14 IH (SEQ ID NO:26), wherein X 13 =S or L and X 14 =A or G,
(b) an HVR-H2 comprising the amino acid sequence of GWISPAGGSTDYADSVKG (SEQ ID NO:24),
(c) an HVR-H3 comprising the amino acid sequence of GPFSPWVMDY (SEQ ID NO:25),
(d) an HVR-L1 comprising the amino acid sequence of RASQX 1 VX 2 X 3 X 4 X 5 A (SEQ ID NO:17), wherein X 1 =D or V; X 2 =S or A; X 3 =T or N; X 4 =S or A; X 5 =V or L,
(e) an HVR-L2 comprising the amino acid sequence of X 6 ASFLYS (SEQ ID NO:18) wherein X 6 =S or L, and
(f) an HVR-L3 comprising the amino acid sequence of QQX 7 X 8 X 9 X 10 X 11 X 12 T (SEQ ID NO:19), wherein X 7 =S, F, G, D or Y; X 8 =Y, P, S, or A; X 9 =T or N; X 10 =T, Y, D or S; X 11 =P or L; X 12 =P or T, and wherein the antibody reduces or inhibits the activity of the BACE1 polypeptide.
2. The antibody of claim 1 , wherein the antibody binds to the active site of BACE1.
3. The antibody of claim 1 , wherein the antibody binds to an exosite of BACE1.
4. The antibody of claim 1 , wherein the HVR-H1 comprises an amino acid sequence selected from the group consisting of SEQ ID NO:22 and SEQ ID NO:23.
5. The antibody of claim 1 , wherein the HVR-H1 sequence is SEQ ID NO:23.
6. The antibody of claim 1 , comprising a VH chain having an amino acid sequence selected from SEQ ID NOs: 20 and 21.
7. The antibody of claim 6 , wherein the VH chain amino acid sequence is SEQ ID NO:21.
8. The antibody of claim 1 , wherein the HVR-L1 comprises an amino acid sequence selected from the group consisting of SEQ ID NO:7 and SEQ ID NO:8.
9. The antibody of claim 1 , wherein the HVR-L2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO:9 and SEQ ID NO:10.
10. The antibody of claim 1 , wherein the HVR-L3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:11-16.
11. The antibody of claim 1 , comprising an HVR-L1 sequence of SEQ ID NO:7 or SEQ ID NO:8; an HVR-L2 sequence of SEQ ID NO:9 or SEQ ID NO:10; and an HVR-L3 sequence selected from the group consisting of: SEQ ID NOs:11-16.
12. The antibody of claim 11 , wherein the HVR-L1 sequence is SEQ ID NO:7, the HVR-L2 sequence is SEQ ID NO:9 and the HVR-L3 sequence is SEQ ID NO:12.
13. The antibody of claim 1 , comprising a VL chain sequence having an amino acid sequence selected from the group consisting of: SEQ ID NOs: 1-6.
14. The antibody of claim 13 , wherein the VL chain amino acid sequence is SEQ ID NO:2.
15. The antibody of claim 5 , wherein the HVR-L1 comprises the amino acid sequence of SEQ ID NO:7, the HVR-L2 comprises the amino acid sequence of SEQ ID NO:9 and the HVR-L3 comprises the amino acid sequence of SEQ ID NO:12.
16. The antibody of claim 14 , further comprising a VH chain comprising the amino acid sequence of SEQ ID NO:21.
17. The antibody of claim 1 , which is a monoclonal antibody.
18. The antibody of claim 1 , which is a human, humanized, or chimeric antibody.
19. The antibody of claim 1 , which is an antibody fragment.
20. The antibody of claim 1 , which is a full length IgG1 antibody.
21. An immunoconjugate comprising the antibody of claim 1 and a cytotoxic agent.
22. A pharmaceutical formulation comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.
23. The antibody of claim 1 , wherein the HVR-H1 sequence is SEQ ID NO:22.
24. The antibody of claim 23 , wherein the HVR-L1 sequence is SEQ ID NO:7, the HVR-L2sequence is SEQ ID NO:9 and the HVR-L3 sequence is SEQ ID NO:11.
25. The antibody of claim 23 , wherein the HVR-L1 sequence is SEQ ID NO:7, the HVR-L2 sequence is SEQ ID NO:9 and the HVR-L3 sequence is SEQ ID NO:13.
26. The antibody of claim 23 , wherein the HVR-L1 sequence is SEQ ID NO:7, the HVR-L2 sequence is SEQ ID NO:9 and the HVR-L3 sequence is SEQ ID NO:14.
27. The antibody of claim 23 , wherein the HVR-L1 sequence is SEQ ID NO:8, the HVR-L2 sequence is SEQ ID NO:10 and the HVR-L3 sequence is SEQ ID NO:15.
28. The antibody of claim 23 , wherein the HVR-L1 sequence is SEQ ID NO:7, the HVR-L2 sequence is SEQ ID NO:9 and the HVR-L3 sequence is SEQ ID NO:16.